|
Sir Richard Sykes became Chairman of NHS London in December 2008.
He was awarded a first class honours degree in Microbiology from Queen Elizabeth College, University of London, a PhD in Microbiology from Bristol University, and a DSc from the University of London. He received a knighthood in the 1994 New Year’s Honours list for services to the pharmaceutical industry.
Before joining NHS London, Sir Richard was Rector of Imperial College London. Prior to Imperial, he had a thirty year career in pharmaceutical industry with Glaxo, subsequently Glaxo Wellcome, where he was Chairman and Chief Executive, and then GlaxoSmithKline which he left as Chairman in 2002.
Sir Richard serves on a number of scientific, higher education and government committees. He is a Director of the Eurasian Natural Resources Corporation and Lonza AG, and is a Trustee of the Masdar Institute of Science and Technology, a Council member of the International Advisory Council of King Abdullah University of Science & Technology (KAUST), a Trustee of Marlborough College and the newly appointed Chairman of the Careers Research and Advisory Centre (CRAC Ltd).
Internationally, he is Chairman of the International Advisory Board, A*STAR Biomedical Research Council, Singapore and a member of the International Advisory Panel of Temasek which owns and manages the Singapore Government’s direct investments.
Sir Richard holds a number of degrees and awards from institutions both in the UK and overseas. He is a Fellow of the Royal Society and Academy of Medical Sciences, an Honorary Fellow of the Royal Academy of Engineering, Royal Society of Chemistry, Royal Pharmaceutical Society, Royal College of Pathologists and Royal College of Physicians.
He is a Fellow of Imperial College School of Medicine, King’s College London, a Fleming Fellow at Lincoln College and, an Honorary Fellow of the University of Wales, Cardiff and the University of Central Lancashire.
He was awarded Honorary Citizenship of Singapore in 2004 for his contribution to the development of the country’s biomedical sciences industry.
|